PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis

• Market Cap: C$7.02M
• Dividend Yield: N/A
• Average Volume (3M): 110.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: N/A
• EPS Growth: 81.01%
• Country: CA
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.11
• Shares Outstanding: 14,046,870
• 10 Day Avg. Volume: 77,322
• 30 Day Avg. Volume: 110,395
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.48 ▼(-5.88% Downside)

The score is held down primarily by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals also remain bearish with the stock below major moving averages and negative MACD. Corporate events provide some support via financing and product/distribution initiatives, but do not offset the underlying profitability and balance-sheet challenges.

Positive Factors

Low reported debt

Zero reported debt in the trailing twelve months reduces near-term refinancing pressure and lowers immediate interest obligations. This durable structural relief gives management more time to execute on commercialization or cost-reduction plans before needing new debt financing, improving short-term solvency.

Reduced cash burn in 2024

A materially lower cash burn in 2024 versus prior years indicates improved operational efficiency or cost controls. Sustained lower burn extends the company’s runway, reduces near-term financing frequency, and if maintained, strengthens the firm’s ability to reach revenue inflection without constant external capital.

Active financing and distribution initiatives

Recent private placement and product/distribution initiatives show management is proactively securing capital and building commercial channels. These structural actions can materially improve liquidity and market access if executed, enabling longer-term development of revenue streams and partnership-driven growth.

Negative Factors

No recorded revenue

Absence of recorded revenue across reported periods means the firm's business model remains unproven and product-market fit is unvalidated. Over a multi-month horizon this limits internal cash generation, increases dependence on financing, and heightens execution risk tied to achieving commercial traction.

Persistent operating cash burn

Consistent negative operating and free cash flow, including a TTM operating cash burn of ~1.7M, is a structural weakness. It erodes liquidity, forces repeated external funding, and raises dilution and execution risk unless the company achieves sustainable revenues or permanent cost reductions.

Negative shareholders' equity

Accumulated deficits and negative equity limit financial flexibility and constrain strategic options. This structural capital shortfall can hinder partnerships, increase fundraising costs, and make future financing dilutive, posing a lasting constraint on the company’s ability to scale operations.

PanGenomic Health, Inc. Class A Business Overview & Revenue Model

Company Description

Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provides consumers with a knowledge base tailored to an individual's unique user profile; and the PlantGx Platform, a digital therapeutics clinic platform that provides health practitioners with access to user health data enabled from the Nara App by the patient and to receive patient referrals. The company was formerly known as Zetta Capital Corp. and changed its name to PanGenomic Health Inc. in December 2021. Pangenomic Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

How the Company Makes Money

PanGenomic Health, Inc. generates revenue primarily through subscription services to its digital health platform. Users pay for access to personalized recommendations and insights based on their genomic data. Additionally, the company may earn revenue through partnerships with healthcare providers and wellness brands, offering them access to its platform for broader distribution and integration of personalized health solutions. The company may also monetize aggregated and anonymized data insights for research and development purposes in collaboration with academic and commercial partners.

PanGenomic Health, Inc. Class A Financial Statement Overview

Summary

Very weak fundamentals: no recorded revenue across periods provided, persistent net losses (TTM net loss ~3.4M), ongoing negative operating/free cash flow (TTM operating cash burn ~1.7M), and consistently negative shareholders’ equity (2022 through TTM). Zero reported debt in TTM reduces near-term refinancing pressure, but overall indicates continued financing dependence.

Income Statement

Across the historical annual reports and TTM (Trailing-Twelve-Months), the company shows no recorded revenue and persistent losses. Losses remain sizable in TTM (Trailing-Twelve-Months) (net loss of ~3.4M) and were also severe in 2022 (net loss of ~20.3M), indicating an unproven/unstable earnings model. A modest positive is that losses in some years (e.g., 2023 vs. 2022) appear to have narrowed, but the overall profile is still characterized by ongoing negative profitability and no visible top-line traction in the provided data.

Balance Sheet

The balance sheet is weakened by consistently negative shareholders’ equity from 2022 through TTM (Trailing-Twelve-Months), which signals accumulated deficits and limits financial flexibility. Total debt is currently reported as zero in TTM (Trailing-Twelve-Months) (and 2024), which reduces near-term refinancing pressure; however, the company previously carried meaningful debt (e.g., 2023). Total assets remain small in absolute terms, and the negative equity position is the key constraint and risk factor.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are negative in every period shown, including TTM (Trailing-Twelve-Months) (operating cash burn of ~1.7M). While free cash flow “growth” prints positive in some periods, it is occurring off a negative base (i.e., still burning cash). A relative positive is that cash burn in 2024 was much lower than in several prior years, but TTM (Trailing-Twelve-Months) burn remains material and implies continued dependence on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-471.00	―	-681.43K	-11.11K	-2.13K	0.00
EBITDA	-3.37M	―	-2.71M	-3.57M	-847.50K	-1.81K
Net Income	-3.41M	-3.80K	-2.97M	-20.35M	-2.65M	-139.99K
Balance Sheet
Total Assets	270.90K	39.16K	71.48K	504.14K	2.58M	147.22K
Cash, Cash Equivalents and Short-Term Investments	82.16K	1.31K	12.56K	88.53K	1.35M	38.23K
Total Debt	0.00	0.00	964.75K	101.77K	0.00	27.50K
Total Liabilities	2.04M	2.44M	2.22M	719.25K	334.45K	136.27K
Stockholders Equity	-1.77M	-2.41M	-2.14M	-215.11K	2.24M	10.95K
Cash Flow
Free Cash Flow	-1.70M	-58.25K	-1.57M	-2.79M	-1.07M	-37.52K
Operating Cash Flow	-1.70M	-58.25K	-1.57M	-2.78M	-1.06M	-37.52K
Investing Cash Flow	0.00	0.00	-3.14K	-52.13K	-604.91K	-100.00K
Financing Cash Flow	1.75M	47.00K	1.50M	1.57M	2.97M	173.50K

PanGenomic Health, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.63, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NARA.

PanGenomic Health, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADK	50 Neutral	C$35.52M	-6.08	―	―	-48.53%	-9.66%
AIDR	48 Neutral	C$65.43M	-4.30	-207.53%	―	―	7.04%
NDAT	46 Neutral	C$826.55K	-2.70	-40.64%	―	-100.00%	65.85%
UDOC	44 Neutral	C$12.09M	-2.95	―	―	―	48.94%
NARA	42 Neutral	C$7.02M	-1.52	―	―	―	81.01%
DMED	33 Underperform	C$7.64M	-4.83	―	―	―	-67.11%

PanGenomic Health, Inc. Class A Corporate Events

PanGenomic Health Launches $2 Million Private Placement to Bolster Working Capital and Reduce Debt

PanGenomic Health Inc. has announced a non-brokered private placement of up to 4,000,000 units at $0.50 per unit, for total gross proceeds and debt settlement of up to $2 million. Each unit comprises one Class A common share and one warrant exercisable at $0.75 for two years, with the funds earmarked for general working capital and settling outstanding indebtedness, including amounts owed to directors and officers. The offering, subject to a four-month-plus-one-day hold and closing no earlier than five business days after the announcement, will see participation from company insiders and is structured to qualify for exemptions from formal valuation and minority shareholder approval requirements under Canadian securities rules, underscoring a balance between near-term balance sheet support and adherence to related-party transaction safeguards for existing shareholders.

PanGenomic Health Enters Agreement with Ayla BioScience for Exclusive Distribution

PanGenomic Health Inc. has signed a non-binding letter of intent with Ayla BioScience to establish an exclusive distribution agreement and a share purchase agreement. This collaboration will allow PanGenomic to distribute Ayla’s Zeotech products in Canada as part of a personalized medicine solution, potentially enhancing its market presence in the natural health sector. The agreement also includes an equity investment by PanGenomic in Ayla BioScience, indicating a strategic move to strengthen its product offerings and market positioning.